Immunomedics, Inc. (IMMU): Price and Financial Metrics


Immunomedics, Inc. (IMMU)

Today's Latest Price: $41.32 USD

0.98 (-2.32%)

Updated Jul 10 4:00pm

Add IMMU to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

IMMU Stock Summary

  • IMMU's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,433.3 -- higher than 98.25% of US-listed equities with positive expected earnings growth.
  • For IMMU, its debt to operating expenses ratio is greater than that reported by just 7.23% of US equities we're observing.
  • IMMU's price/sales ratio is 32,341.66; that's higher than the P/S ratio of 100% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Immunomedics Inc, a group of peers worth examining would be URGN, GENE, NK, ADVM, and CYAD.
  • IMMU's SEC filings can be seen here. And to visit Immunomedics Inc's official web site, go to www.immunomedics.com.
IMMU Daily Price Range
IMMU 52-Week Price Range

IMMU Stock Price Chart Technical Analysis Charts


IMMU Price/Volume Stats

Current price $41.32 52-week high $42.94
Prev. close $42.30 52-week low $8.80
Day low $41.04 Volume 1,791,382
Day high $42.94 Avg. volume 3,839,101
50-day MA $34.13 Dividend yield N/A
200-day MA $21.76 Market Cap 9.54B

Immunomedics, Inc. (IMMU) Company Bio


Immunomedics, Inc. focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company was founded in 1982 and is based in Morris Plains, New Jersey.


IMMU Latest News Stream


Event/TimeNews Detail
Loading, please wait...

IMMU Latest Social Stream


Loading social stream, please wait...

View Full IMMU Social Stream

Latest IMMU News From Around the Web

Below are the latest news stories about Immunomedics Inc that investors may wish to consider to help them evaluate IMMU as an investment opportunity.

Lifshitz Law Firm, P.C. Announces Investigation of Acer Therapeutics, Inc. (ACER), Advanced Disposal Services, Inc. (ADSW), Apyx Medical Corporation (APYX), Honeywell International Inc. (HON), Immunomedics, Inc. (IMMU), National General Holdings Corp. (NGHC) and Zuora, Inc. (ZUO)

Acer Therapeutics, Inc. (ACER)

Yahoo | July 9, 2020

Immunomedics: A Solid Cancer Research Play

The company has a strong pipeline of antibody-drug conjugates Continue reading...

Yahoo | July 8, 2020

Is Immunomedics (IMMU) Outperforming Other Medical Stocks This Year?

Is (IMMU) Outperforming Other Medical Stocks This Year?

Yahoo | July 7, 2020

Immunomedics' Shares Rise on Positive Breast Cancer Drug Data

Shares of Immunomedics (IMMU) rise after it announces positive phase III data for its breast-cancer drug, Trodelvy.

Yahoo | July 7, 2020

The Daily Biotech Pulse: Novavax Lands $1.6B For COVID-19 Vaccine, Amgen Prevails In Avastin Biosimilar Lawsuit, Cellectis Study Placed On Clinical Hold

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * Akero Therapeutics Inc (NASDAQ: AKRO) * Amgen, Inc. (NASDAQ: AMGN) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Champions Oncology Inc (NASDAQ: CSBR) * Crispr Therapeutics AG (NASDAQ: CRSP) * Cytokinetics, Inc. (NASDAQ: CYTK) * DexCom, Inc. (NASDAQ: DXCM) * Eli Lilly And Co (NYSE: LLY) * Fate Therapeutics Inc (NASDAQ: FATE) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Hologic, Inc. (NASDAQ: HOLX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Illumina, Inc. (NASDAQ: ILMN) * Immunomedics, Inc. (NASDAQ: IMMU) (announced positive late-stage...

Yahoo | July 7, 2020

Read More 'IMMU' Stories Here

IMMU Price Returns

1-mo 36.32%
3-mo N/A
6-mo 114.15%
1-year 181.66%
3-year 365.32%
5-year 872.24%
YTD 95.27%
2019 48.28%
2018 -11.70%
2017 340.33%
2016 19.54%
2015 -36.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8067 seconds.